![]() | |
Clinical data | |
---|---|
Trade names | Esbriet, Pirespa, Etuary |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615008 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 50–58%[7] |
Metabolism | Liver (70–80% CYP1A2-mediated; minor contributions from CYP2C9, CYP2C19, CYP2D6 and CYP2E1)[7] |
Elimination half-life | 2.4 hours[7] |
Excretion | Urine (80%)[7] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.150.129 |
Chemical and physical data | |
Formula | C12H11NO |
Molar mass | 185.226 g·mol−1 |
3D model (JSmol) | |
Solubility in water | 10mg/mL at 60 °C |
| |
| |
![]() ![]() |
Pirfenidone, sold under the brand name Pirespa among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
It was first approved in Japan for the treatment of people with idiopathic pulmonary fibrosis after clinical trials in 2008. It was approved for use in the European Union in 2011,[8][6] in Canada in 2012,[4] and in the United States in October 2014.[5][9]
It is available as a generic medication.[10]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search